Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge

NCT ID: NCT03061227

Last Updated: 2020-05-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-10
• Study Completion Date: 2020-04-30

Brief Summary

The investigators previously characterized a phenotype with non-suppressed glucagon at 120 minutes after standardized oral glucose load. This phenotype is associated with healthy metabolic traits such as lower BMI, higher insulin sensitivity and lower liver fat content. Glucagon is a pleiotropic hormone that, besides its main action on increasing endogenous glucose production, also reduces appetite and increases basal energy expenditure. The aims of this study are to i. detect functional differences in the appetite-related central nervous system (CNS) areas between the suppressed and non-suppressed glucagon phenotype ii. mimick the non-suppressed glucagon phenotype in those participants who suppress glucagon by administering a very-low-dose glucagon infusion and retest them.

Conditions

Metabolic Syndrome; Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Intravenous glucagon

Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test

Group Type: ACTIVE_COMPARATOR

Intravenous glucagon

Intervention Type: DRUG

Randomized application of glucagon or saline during oral glucose tolerance test

Intravenous saline

Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test

Group Type: PLACEBO_COMPARATOR

Intravenous saline

Intervention Type: DRUG

Randomized application of glucagon or saline during oral glucose tolerance test

Interventions

Intravenous glucagon

Randomized application of glucagon or saline during oral glucose tolerance test

Intervention Type: DRUG

Intravenous saline

Randomized application of glucagon or saline during oral glucose tolerance test

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• BMI 18.5- 29.9 kg/m2
• written informed consent

Exclusion Criteria

• Current

1. febrile infection with temperatures> 38.5 ° C in the last 14 days

2. Blood donation within the last 12 weeks Pre-study Inclusion

• Chronic diseases:

1. Diabetes mellitus

2. Known liver diseases (hepatitisB/C, hemochromatosis, NASH)

3. Chronic inflammatory diseases (rheumatoid arthritis, Crohn's disease, ulcerative colitis) chronic renal insufficiency

4. Cancer (known malignant disease)

5. psychiatric diagnoses (bipolar disorder, schizophrenia, psychoses, depression, agoraphobia)

6. Persons with non-removable metal parts, e.g:

• pacemaker
• artificial heart valves
• metal prostheses
• implanted magnetic metal parts (screws, plates of operations)
• spiral
• metal slivers / garnet splinters
• fixed braces
• Acupuncture needle
• Insulin pump
• totally implantable venous access device (port)
• tattoos, metallic eye shadows

7. Persons with impaired sensitivity and / or increased sensitivity to heating of the body

8. Medical history of venous thromboembolism

9. alcohol consumption of more than 50g / day

10. In physical examination:

blood pressure > 160/100 mmHg pathologic cardiac murmurs (diastolic or systolic louder than 2/6)

11. in the blood test: fasting glucose ≥ 125 mg/dl or HbA1c ≥ 6.5% AST or ALT> 2.5x upper limit of the reference range (> 125 U/l) Hb <12 g/dl C reactive protein (CRP) > 5 mg / dL or leukocytes> 15000/μl

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital Tuebingen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University Hospital Tübingen

Tübingen, , Germany

Countries

Germany

Other Identifiers

529_2016BO1

Identifier Type: -

Identifier Source: org_study_id